GlycoNex Inc. and Nippon Kayaku Enter Collaboration to Advance Next-Gen ADC Candidate GNX201-ADC
“GlycoNex has long been dedicated to advancing anti-glycan antibodies and tumor glycobiology, and ADCs represent a natural extension of that scientific focus,” said Dr. Mei-Chun Yang, CEO of GlycoNex. “We are honored to collaborate with Nippon Kayaku to combine our complementary R&D strengths, clinical development capabilities, and regulatory expertise to accelerate GNX201-ADC and advance the program toward clinical studies.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.